In preclinical studies, work is already in progress to develop this second-generation CAR-T, specific for markers of the tumor-initiating cell population, such as CD133 (129), to demonstrate their selectivity and efficacy against refractory, highly aggressive tumors with a high rate of metastasis production. The gene discussed is PROM1; the disease is neoplasm.